<PAPER>
  <mode2 name="12151625_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Promotion of Altered Hepatic Foci by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and 17&#946;-estradiol in Male Sprague-Dawley Rats <CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">The determination of differences in hormonal regulation of tumor promotion-related response to 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) between males and females may identify factors contributing to the female-specific hepatocarcinogenicity of TCDD in rats.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      <s sid="3">In the current study, diethylnitrosamine-initiated male Sprague-Dawley rats were exposed to TCDD or corn oil vehicle in the presence and absence of 17&#946;-estradiol (E2), and cell proliferation and development of preneoplastic altered hepatic foci (AHF) were determined.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
      <s sid="4">After 30 weeks of exposure, &#947;-glutamyltranspeptidase (GGT)-positive AHF and the number of placental glutathione-s-transferase (PGST)-positive AHF were significantly higher in TCDD-treated rats than in control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="5">Both the number and volume fraction of GGT-positive AHF were significantly lower in rats cotreated with E2 regardless of TCDD exposure compared with corresponding non-E2-treated groups and were unaffected by TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="6">In contrast, the number of PGST-positive AHF was significantly higher in E2-treated rats in the absence of TCDD treatment.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="7">In addition, whereas E2 had no effect on the volume fraction of PGST-positive foci, the levels in rats cotreated with both E2 and TCDD were significantly higher than in controls.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="8">No differences were observed in cell proliferation between TCDD-treated and control rats, although cell proliferation was lower in rats exposed to E2 compared with placebo controls.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="9">The weaker potency of tumor promotion and lack of induction of cell replication and DNA damage in male rats likely explain the female-specific hepatocarcinogenicity of TCDD in chronic bioassays.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE/>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="10">The ubiquitous environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a multisite rodent carcinogen in both sexes (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-1">Kociba et al., 1978</xref>; <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">NTP, 1982</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
        <s sid="11">TCDD is considered a nongenotoxic carcinogen because it fails to exhibit genotoxicity in in vivo and in vitro assays (<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">Kociba, 1984</xref>; <xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">Poland and Glover, 1979</xref>; <xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-1">Turteltaub et al., 1990</xref>; <xref class="xref-bibr" href="#ref-53" rid="xref-ref-53-1">Wassom et al., 1977</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
        <s sid="12">In a two-stage initiation-promotion model for hepatocarcinogenesis, TCDD is a potent promoter in rodent skin, liver, and lung (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">Beebe et al., 1995</xref>; <xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-1">Pitot et al., 1980</xref>; <xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">Poland et al., 1982</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="13">In tumor promotion studies, TCDD promotes the formation of liver tumors (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-2">Pitot et al., 1980</xref>; <xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-1">Walker et al., 2000</xref>) and various phenotypes of preneoplastic enzyme-altered hepatocellular foci (AHF) (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">Flodstr&#246;m and Ahlborg, 1992</xref>; <xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-3">Pitot et al., 1980</xref>; <xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-1">Waern et al., 1991</xref>) in initiated rats at a similar exposure level reported in the chronic 2-year bioassay by Kociba et al.(1978).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
        <s sid="14">Hepatic tumor development after chronic exposure to TCDD is specific to female rats (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-2">Kociba et al., 1978</xref>; <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-2">NTP, 1982</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="15">Although the early Ah receptor-mediated molecular events are well characterized (<xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-1">Schmidt and Bradfield, 1996</xref>; <xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-1">Sutter and Greenlee, 1992</xref>; <xref class="xref-bibr" href="#ref-41" rid="xref-ref-41-1">Swanson and Bradfield, 1993</xref>), it is not currently known how TCDD, the most potent ligand for the Ah-receptor, causes cancer in rats.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="16">The induction of preneoplastic AHF by TCDD in chronic tumor promotion studies is well characterized.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="17">Chronic exposure of female Sprague-Dawley rats to more than 100 ng/kg/day of TCDD significantly induces AHF expressing the placental form of glutathione-s-transferase (PGST) (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">Bager et al., 1997</xref>; <xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-2">Flodstr&#246;m and Ahlborg, 1992</xref>; <xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">Maronpot et al., 1993</xref>; <xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-1">Tritscher et al., 1995</xref>; <xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-1">van der Plas et al., 1999</xref>; <xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-2">Walker et al., 2000</xref>) and AHF expressing &#947;-glutamyltranspeptidase (GGT) (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">Flodstr&#246;m and Ahlborg, 1989</xref>; <xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">Flodstr&#246;m et al., 1991</xref>; <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">Graham et al., 1988</xref>; <xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">Hemming et al., 1995</xref>; <xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-2">Waern et al., 1991</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-1">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        <s sid="18">To elucidate biological and physiological contributing factors to the mechanism of tumor promotion, studies have investigated the hormonal regulation of tumor promotion by TCDD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="19">Ovarian hormones have been shown to contribute to tumor promotion by TCDD in female Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">Lucier et al., 1991</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-2">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="20">Ovariectomized (OVX) rats had significantly diminished development of GGT-positive AHF induced by TCDD compared with sham-operated rats (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-2">Lucier et al., 1991</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="21">Additionally, the induction of GGT-positive AHF by TCDD in intact female rats is not observed in OVX female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-3">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
        <s sid="22">Oxidative DNA damage and increased cell proliferation may be critical factors that contribute to the process of tumor promotion (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">Ames and Gold, 1990</xref>, <xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">1991</xref>; <xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">Butterworth et al., 1992</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="23">Left unrepaired, lesions that form as a result of oxidative DNA damage may be fixed into the genome during subsequent cell replication.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="24">Resulting mutations in genes involved in growth and differentiation may, therefore, result in an increase in the population of initiated hepatocytes and altered growth properties of initiated hepatocytes undergoing clonal expansion.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="25">The induction of cell proliferation and 8-oxo-deoxyguanosine (8-oxo-dG) oxidative DNA adducts depends on ovarian hormones (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-3">Lucier et al., 1991</xref>; <xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-1">Tritscher et al., 1996</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-4">Wyde et al., 2001a</xref>,<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-1">b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="26">TCDD-induced cell proliferation after 30 weeks of exposure is observed in intact, but not OVX, rats (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-4">Lucier et al., 1991</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-5">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="27">Similarly, 8-oxo-dG adducts are significantly induced by TCDD in intact rats but not OVX female rats (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-2">Tritscher et al., 1996</xref>; <xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-2">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="28">Additionally, TCDD-induced adduct formation is observed in female rats but not male rats (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-3">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="29">These data provide further evidence of ovarian hormone modulation of 8-oxo-dG adduct formation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="30">Through increased cell proliferation in combination with increased DNA damage, TCDD may indirectly induce mutation frequency via an ovarian hormone-dependent mechanism.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="31">The endogenous estrogen 17&#946;-estradiol (E2) may contribute to the ovarian hormone-modulated mechanism of TCDD-induced tumor promotion in female rats.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="32">It has been shown that continuous treatment of OVX female rats with estradiol can compensate for the inhibitory effect of ovariectomy on TCDD-induced tumor promotion (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-4">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="33">Although E2 itself does not induce AHF formation or cell proliferation in OVX Sprague-Dawley rats, it does enhance TCDD-induced increases in GGT-positive AHF and cell proliferation (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-6">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="34">No significant induction of GGT-positive AHF is observed in OVX rats without E2 exposure.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="35">In OVX rats receiving supplemental E2, TCDD significantly induces hepatocyte proliferation (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-7">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="36">Additionally, 8-oxo-dG adduct formation is induced by TCDD in OVX female rats receiving supplemental E2 (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-5">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="37">These data support the hypothesis that E2 enhances tumor promotion by TCDD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="38">The hormonal regulation of AHF, cell proliferation, and oxidative DNA damage is consistent with the sex and ovarian hormone influence on induction of hepatic tumor incidence by TCDD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="39">TCDD induces the expression and activity of cytochrome P-450 isozymes that metabolize E2 to catechol estrogens in Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">Drahushuk et al., 1996</xref>; <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-2">Graham et al., 1988</xref>; <xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">Hakansson et al., 1994</xref>; <xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-1">Vanden Heuvel et al., 1994</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="40">Catechol estrogens are rodent carcinogens (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-1">Liehr et al., 1986</xref>; <xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">Newbold and Liehr, 2000</xref>) that may contribute to estrogen-induced carcinogenesis through reactive oxygen intermediates (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">Li et al., 1995</xref>; <xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">Liehr, 1994</xref>; <xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-1">Liehr and Roy, 1990</xref>; <xref class="xref-bibr" href="#ref-58" rid="xref-ref-58-1">Yager and Liehr, 1996</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="41">TCDD-induced tumor promotion may involve catechol estrogen-derived reactive oxygen formation or leakage of oxygen radicals from the active site of TCDD-inducible cytochrome P-450, including P-4501A1 (<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">Park et al., 1996</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="42">Just as E2 or 4-hydroxyestradiol increases oxidative DNA damage in the Syrian hamster model (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">Han and Liehr, 1994</xref>), TCDD induces oxidative DNA damage in female Sprague-Dawley rat liver.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="43">Additionally, estrogen-modulated cell proliferation may, in combination with oxidative damage, contribute to the mechanism of tumor promotion by TCDD.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
        <s sid="44">In all likelihood, TCDD acts through multiple mechanisms, both estrogen modulated and estrogen independent, to induce hepatocarcinogenesis and liver tumor promotion.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="45">Because TCDD is a potent liver hepatocarcinogen in female but not male rats, most studies in the past 2 decades have further investigated the promotional effects of TCDD on liver tumor promotion in female rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="46">These studies have mainly characterized temporal and dose-related effects of TCDD on the formation of AHF in female rats (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">Dragan et al., 1992</xref>; <xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-2">Maronpot et al., 1993</xref>; <xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-4">Pitot et al., 1980</xref>; <xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">Teeguarden et al., 1999</xref>; <xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-3">Walker et al., 2000</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="47">Despite extensive studies, little is known about the mechanism of induction of liver tumor by TCDD in the female rat.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="48">Advances have been made in the understanding of the role of ovarian hormones and E2 in TCDD-induced tumor promotion (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-6">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="49">However, further investigations are required to determine the contribution of these factors and identify key events in the mechanism of tumor promotion and hepatocarcinogenesis by TCDD.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
        <s sid="50">Although comparisons between control and TCDD-treated rats have effectively identified TCDD-induced responses, the identification of responses in female rats not occurring in male rats may indicate critical contributing factors or key events in the mechanism of tumor promotion by TCDD in Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="51">The aim of the current study was to investigate tumor promotion by TCDD in male rats to elucidate key factors and critical events in the mechanism of TCDD in female rats.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
        <s sid="52">To determine differences in tumor promotion between male and female rats, diethylnitrosamine (DEN)-initiated male rats were treated with TCDD for 30 weeks.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="53">TCDD-induced alterations in GGT- and PGST-positive AHF formation and development as markers of tumor promotion were analyzed and compared with results from similarly treated female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-8">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="54">Additionally, the effects of TCDD on the incorporation of 5`-bromodeoxyuridine (BrdU) into the DNA of replicating hepatocytes were determined in male rats and compared with results from similarly treated female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-9">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="55">Because tumor development is specific to female Sprague-Dawley rats, it was expected that exposure to TCDD in male rats would not result in a significant increase in preneoplastic AHF or an induction of hepatocyte proliferation.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
        <s sid="56">However, because E2 potentiates TCDD-induced increases in GGT-positive AHF and cell proliferation in female rats, it may be expected to act similarly in male rats modulating TCDD-induced development of AHF lesions and cell proliferation.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp5" novelty="None" advantage="None"/></s>
        <s sid="57">To test this hypothesis, male rats were treated with TCDD in the presence and absence of E2 administered by subcutaneously implanted pellets.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>MATERIALS AND METHODS</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animals.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="58">Male Sprague-Dawley rats (Charles River, Raleigh, NC) were treated as previously described (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-1">Wyde et al., 2000</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="59">Rats were housed 2 per cage under conditions of controlled temperature (70 &#177; 0.5&#176;F), humidity (50 &#177; 5%), and lighting (12 h light/12 h dark) and received food and water ad libitum.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="60">Rats were divided into 4 groups of 8 rats each.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="61">All rats were initiated with 175 mg DEN/kg (administered intraperitoneally) at 10 weeks of age.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="62">One week after initiation, 2 groups were implanted with 90-day release pellets containing 0 mg (placebo) and 2 groups were implanted with pellets containing 0.18 mg of E2/pellet (Innovative Research).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="63">New pellets were implanted after 90 days.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="64">Starting 1 week later, 1 group of placebo-treated rats and 1 group of E2-treated rats were treated once per week with an oral gavage dose of 700 ng TCDD/kg for 30 weeks.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="65">This dose of TCDD is equivalent to a daily average dose of 100 ng TCDD/kg/day, comparable to exposure levels that induced liver tumors in female rats in the chronic bioassay described by Kociba et al.(1978).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="66">The remaining placebo and E2 groups were treated weekly by oral gavage with corn oil vehicle for 30 weeks.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="67">Osmotic pumps (Alzet model 2ML1; 10 &#956;l/h delivery rate; Alzet Corp., Palo Alto, CA) containing 30 mg/ml 5-bromo-2`-deoxyuridine in saline were implanted subcutaneously 7 days before necropsy to allow for evaluation of hepatocyte proliferation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="68">Rats were killed by asphyxiation with carbon dioxide, and liver tissues were removed, weighed, sectioned, and frozen in liquid nitrogen.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="69">Liver slices were also fixed in 4% paraformaldehyde or ethanol and embedded in paraffin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="70">Serial liver sections (5 &#956;m thick) were cut and placed on microscope slides.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">AHF formation.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="71">PGST immunohistochemistry, GGT enzyme histochemistry, and stereological analysis were performed on paraformaldehyde- and ethanol-fixed liver sections, respectively, as previously described (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-10">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="72">The promotion index was calculated using the following formula:<span class="disp-formula" id="disp-formula-1"><img alt="Formula" class="math tex" src="295/embed/tex-math-1.gif"/></span>where V<sub>f</sub> is the volume fraction of treated rats, V<sub>c</sub> is the volume fraction in control rats, and mmol per week is the mean amount of promoter administered to each rat during the period of promotion.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="73">The calculation for the promotion index allows for comparisons of potency of tumor promotion activity between sexes, species, and strains from different studies.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cell replication.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="74">The incorporation of BrdU into DNA of replicating hepatocytes was determined by immunohistochemistry according to the methods of Goldsworthy et al.(1991).<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="75">Positively stained nuclei were scored in at least 1000 hepatocytes determined to be histopathologically nonfocal as assessed by a trained pathologist in hematoxylin and eosin counterstained tissue.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
        <s sid="76">The BrdU labeling index is expressed as the percentage of all nuclei counted that were positively labeled with BrdU.<CoreSc1 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Statistics.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="77">Because of the presence of a large number of zero values in the GGT AHF data, these data sets were analyzed by nonparametric statistical methods.<CoreSc1 atype="GSC" type="Met" conceptID="Met13" novelty="None" advantage="None"/></s>
        <s sid="78">Significant between-group differences were first determined by one-way Kruskal-Wallis tests (p &lt; 0.05).<CoreSc1 atype="GSC" type="Met" conceptID="Met14" novelty="None" advantage="None"/></s>
        <s sid="79">Because these were significant, pairwise group comparisons were subsequently made by pairwise rank-order-based Mann-Whitney U-tests (p &lt; 0.05).<CoreSc1 atype="GSC" type="Met" conceptID="Met15" novelty="None" advantage="None"/></s>
        <s sid="80">Untransformed PGST-positive AHF and BrdU LI data exhibited homogeneity of variance when tested by Bartlett&#8217;s tests.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
        <s sid="81">Log10 transformed CYP data exhibited homogeneity of variance when tested by Bartlett&#8217;s tests.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
        <s sid="82">Significant differences between all groups were determined by one-way ANOVA.<CoreSc1 atype="GSC" type="Met" conceptID="Met16" novelty="None" advantage="None"/></s>
        <s sid="83">Because the ANOVA tests indicated significant between-group effects, pairwise group comparisons were then tested using Fisher&#8217;s least significant difference test (p &lt; 0.05).<CoreSc1 atype="GSC" type="Met" conceptID="Met17" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Real-time and quantitative RT-PCR.</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="84">Quantitation of CYP1A1 messenger RNA levels was determined using real-time fluorescence detection reverse-transcriptase polymerase chain reaction (RT-PCR) (<xref class="xref-bibr" href="#ref-50" rid="xref-ref-50-1">Walker, 2001</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met18" novelty="None" advantage="None"/></s>
        <s sid="85">Total RNA was isolated from frozen liver samples using an acid-guanidinium-phenol-chloroform technique (Tri-reagent) (Sigma, St. Louis, MO).<CoreSc1 atype="GSC" type="Met" conceptID="Met19" novelty="None" advantage="None"/></s>
        <s sid="86">Real-time RT-PCR reactions were prepared using a Perkin-Elmer Syber Green RT-PCR kit according the manufacturer&#8217;s recommendations with the modification of the use of a CYP1A1-specific reverse-transcription primer (5`cca atc act gtg).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="87">Thermal cycling and real-time detection of the Syber Green-associated fluorescence was performed using an Applied Biosystems 7700 Sequence Detection system with default temperature parameters.<CoreSc1 atype="GSC" type="Met" conceptID="Met20" novelty="None" advantage="None"/></s>
        <s sid="88">PCR primers were designed using Primer Express; forward, 5`-tcaaagagcactacaggacatttg; reverse, 5`gggttggttaccaggtacatgag.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="89">Quantitation of CYP1A1 was determined by interpolation of the sample-specific cycle-threshold value against a standard curve prepared on the same plate using a 10-fold serial dilution of a quantitated liver total RNA sample.<CoreSc1 atype="GSC" type="Met" conceptID="Met21" novelty="None" advantage="None"/></s>
        <s sid="90">The expression level of CYP1A1 in the quantitated liver total RNA sample was determined using a competitive RT-PCR titration assay as previously described (<xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-1">Walker et al., 1999</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met22" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Formation and Development of GGT-Positive AHF</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="91">In male rats treated weekly with 700 ng TCDD/kg (a daily average dose of 100 ng/kg/day) for 30 weeks, there were no significant differences in the number of GGT-positive AHF/cm<sup>3</sup> compared with control male rats (Fig. 1).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
        <s sid="92">Additionally, there were no significant differences in the number of GGT-positive AHF/cm<sup>3</sup> between TCDD-treated and control rats in the presence of E2.<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="93">However, in rats exposed to E2, the number of GGT-positive AHF/cm<sup>3</sup> was significantly lower than in male rats not receiving E2.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="94">The median number of GGT-positive AHF/cm<sup>3</sup> was 59.7 and 0 in placebo-control and E2-treated male rats, respectively.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="95">The suppression of GGT-positive AHF/cm<sup>3</sup> by E2 was also observed in rats exposed to TCDD.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="96">In TCDD-treated rats, exposure to E2 resulted in 3.5-fold lower median numbers of GGT-positive AHF/cm<sup>3</sup> than in TCDD-treated rats not exposed to E2.<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="97">The percentage of the liver occupied by GGT-positive AHF (volume fraction) in TCDD-treated rats was significantly higher than in control rats (Fig. 2).<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="98">A 2-fold induction in GGT-positive volume fraction by TCDD was observed with median values of 0.012% and 0.024% in control and TCDD-treated rats, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="99">The GGT-positive volume fraction was significantly lower in male rats receiving E2 than in placebo-control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="100">In rats exposed to TCDD, the volume fraction of GGT-positive AHF was significantly lower in E2-treated rats than in control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="101">These results are similar to the effects of E2 on the number of GGT-positive AHF/cm<sup>3</sup> (see Fig. 1) in both control and TCDD-treated rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Formation and Development of PGST-Positive AHF</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="102">PGST-positive AHF have been demonstrated to represent approximately 97% of all AHF in Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-2">Teeguarden et al., 1999</xref>) and greater than 65% of all AHF in Fischer F344 rats (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">Hendrich et al., 1987</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="103">Therefore, alterations in the development of PGST-positive AHF by TCDD and E2 were analyzed in addition to GGT-positive AHF in male Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="104">In contrast to the observations of the suppressive effects of E2 on GGT positive AHF, the number of PGST-positive AHF/cm<sup>3</sup> in TCDD-treated male rats was significantly higher than in control male rats (Fig. 3).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="105">The mean number of PGST-positive AHF was more than 2-fold higher in TCDD-treated rats than in control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="106">In rats treated with E2, no significant difference was observed between TCDD-treated and control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="107">However, the number of PGST-positive AHF/cm<sup>3</sup> was significantly higher in rats treated with E2 only compared with placebo-controls.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="108">No significant differences were observed in the volume fraction of PGST-positive AHF between TCDD-treated or E2-treated rats compared with placebo-control rats (Fig. 4).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="109">However, in rats exposed to both E2 and TCDD, the volume fraction of PGST-positive AHF was significantly higher than in rats receiving E2 alone.<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="110">The mean volume fraction was 0.8% in E2-treated rats and 2.2% in male rats cotreated with E2 and TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Alterations in Cell Replication</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="111">The effect of TCDD and coexposure to TCDD and E2 on cell proliferation, as determined by the uptake of BrdU into the DNA of replicating hepatocytes, was determined.<CoreSc1 atype="GSC" type="Met" conceptID="Met23" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
        <s sid="112">No significant differences were observed in BrdU labeling index between TCDD-treated and control rats; however, exposure to E2 suppressed the BrdU labeling index more than 5-fold compared with rats receiving placebo pellets (Fig. 5).<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="113">Although the BrdU labeling index in TCDD-treated rats was equivalent between groups receiving E2 or placebo pellets, the BrdU labeling index was significantly higher in rats cotreated with both TCDD and E2 compared with those receiving only E2.<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
        <s sid="114">These data may reflect a suppression of cell proliferation by E2 treatment that is inhibited by TCDD in coexposed rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Relative Potency of Promotion by TCDD</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="115">Relative potency of promoters based on differences in induction of the development of AHF has previously been reported (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">Dragan and Pitot, 1992</xref>; <xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-1">Pitot et al., 1987</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="116">These calculations for the promotion index allow for comparisons of potency of tumor promotion activity among sexes, species, and strains.<CoreSc1 atype="GSC" type="Met" conceptID="Met24" novelty="None" advantage="None"/></s>
        <s sid="117">Promotion index is described by the following formula in which V<sub>f</sub> is the volume fraction of treated rats, V<sub>c</sub> is the volume fraction in control rats, and millimoles per week is the mean amount of promoter administered to each rat during the period of promotion:<span class="disp-formula" id="disp-formula-2"><img alt="Formula" class="math tex" src="295/embed/tex-math-2.gif"/></span>Table 1 shows promotion indices for GGT-positive AHF from the current study in male rats and a prior study in female rats and values previously reported in the literature.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="118">The promotion index calculated from the prior study in similarly treated female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-11">Wyde et al., 2001a</xref>) for TCDD was 2.6 &#215; 10<sup>7</sup> in intact female rats after 30 weeks of exposure (see Table 1).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="119">With the exception of 1 study (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-2">Hemming et al., 1995</xref>), these results are consistent with previously calculated potency of TCDD in female Sprague-Dawley rats ranging from 1.5 &#215; 10<sup>7</sup> to 2.8 &#215; 10<sup>7</sup> (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">Hemming et al., 1993</xref>; <xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-5">Pitot et al., 1980</xref>; <xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-3">Waern et al., 1991</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="120">In male rats, the promotion index was 2.76 &#215; 10<sup>6</sup>, an order of magnitude lower than in female rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="121">In E2-treated male rats, the promotion index of TCDD was 7.7 &#215; 10<sup>4</sup>.<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
        <s sid="122">In female rats, it has been demonstrated that ovarian hormones contribute to TCDD-induced tumor promotion (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-5">Lucier et al., 1991</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-12">Wyde et al., 2001a</xref>) and E2 may supplement for the inhibitory effect of ovariectomy (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-13">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="123">The promotional index in OVX rats in the prior study (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-14">Wyde et al., 2001a</xref>) was 7.5 &#215; 10<sup>5</sup>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="124">The calculated promotion index for TCDD in E2-supplemented OVX rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-15">Wyde et al., 2001a</xref>) was 8.42 &#215; 10<sup>6</sup>, which is 10-fold greater than in OVX rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="125">The value of the promotion index, based on GGT-positive AHF, is consistent with the inhibitory effect of ovariectomy and enhancing effect of E2 on the potency of tumor promotion by TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Expression of CYP1A1</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-22">
        <s sid="126">To determine whether the differences in the AHF promotion were due to differences in the level of responsiveness of male and female rats to TCDD, the expression of CYP1A1 was measured by quantitative RT-PCR (Table 2).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met25" novelty="None" advantage="None"/></s>
        <s sid="127">In control rats, the expression of CYP1A1 was significantly higher in males compared with females.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
        <s sid="128">In male and female TCDD-treated rats, CYP1A1 was significantly higher compared with their respective controls regardless of gender or hormonal status.<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="129">In addition, there was no significant difference between male and females in the level of CYP1A1 expression in similarly treated TCDD-treated groups.<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
        <s sid="130">Of note, the TCDD-induced expression of CYP1A1 was significantly higher in OVX versus intact female rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="131">These data indicate that although the fold induction of CYP1A1 was higher in females, the level to which the male and female rats were induced by TCDD was equivalent.<CoreSc1 atype="GSC" type="Res" conceptID="Res34" novelty="None" advantage="None"/></s>
        <s sid="132">These data are consistent with prior observations that tissue levels of TCDD in male and female rats after similar chronic exposures are equivalent (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-7">Wyde et al., 2001b</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res35" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="133">Given the similarity in the levels of TCDD-induced expression of CYP1A1, it is unlikely that the observed differences in AHF between TCDD-treated groups are due to differences in the level of activation of the Ah receptor.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-23">
        <s sid="134">Because TCDD is not a hepatocarcinogen in male rats, hepatic tumor promotion studies of TCDD have focused on female rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
        <s sid="135">These studies demonstrate dose- and duration-dependent induction of multiple phenotypes of preneoplastic AHF by TCDD in female Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/></s>
        <s sid="136">However, little has been determined regarding the mechanism by which TCDD induces these lesions and, subsequently, liver tumors.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot6" novelty="None" advantage="None"/></s>
        <s sid="137">In the current study, the development of preneoplastic AHF lesions and alterations in cell proliferation were determined as markers and contributors to tumor promotion by TCDD in male Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Met" conceptID="Met26" novelty="None" advantage="None"/></s>
        <s sid="138">TCDD significantly induced the volume fraction of GGT-positive AHF.<CoreSc1 atype="GSC" type="Res" conceptID="Res36" novelty="None" advantage="None"/></s>
        <s sid="139">The volume fraction of AHF is the most applicable in determining the extent and efficacy of tumor promotion (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">Pitot et al., 1989</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
        <s sid="140">However, although the median volume fraction of GGT-positive AHF was induced 2-fold over controls in male rats, in a prior study in female Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-16">Wyde et al., 2001a</xref>), TCDD induced a 14-fold increase in GGT-positive volume fraction.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac44" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res37" novelty="None" advantage="None"/></s>
        <s sid="141">Additional studies in females have consistently demonstrated a 6- to 12-fold induction of GGT-positive AHF volume fraction after 27 to 30 weeks of exposure to TCDD depending on the initiation-promotion protocol (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-2">Flodstr&#246;m and Ahlborg, 1989</xref>; <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-3">Graham et al., 1988</xref>; <xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-6">Lucier et al., 1991</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac45" novelty="None" advantage="None"/></s>
        <s sid="142">Using the GGT-positive AHF data, the promotion index, a measure of potency of tumor promotion, was an order of magnitude higher in female rats than male rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res38" novelty="None" advantage="None"/></s>
        <s sid="143">Taken together, these data indicate that, based on induction of GGT-positive AHF, TCDD is a more potent promoter in female than in male Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-24">
        <s sid="144">TCDD exposure did not significantly induce the number of GGT-positive AHF/cm<sup>3</sup> in male Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res39" novelty="None" advantage="None"/></s>
        <s sid="145">This quantitative measure of AHF tends to reflect the potency and efficacy of initiation (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-2">Pitot et al., 1989</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac46" novelty="None" advantage="None"/></s>
        <s sid="146">In similarly treated female rats, TCDD resulted in an elevated number of GGT-positive AHF/cm<sup>3</sup> (p = 0.085) (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-17">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac47" novelty="None" advantage="None"/></s>
        <s sid="147">Although not statistically significant, an elevated number of GGT-positive AHF/cm<sup>3</sup> is consistent with previous observations of significant increases in GGT-positive AHF/cm<sup>3</sup> by TCDD (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-3">Flodstr&#246;m and Ahlborg, 1989</xref>, <xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-3">1992</xref>; <xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-4">Waern et al., 1991</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res40" novelty="None" advantage="None"/></s>
        <s sid="148">Because comparable doses of DEN were used as the initiating agent in both studies, differences in the number of AHF/cm<sup>3</sup> may reflect differences in contribution of TCDD to continued initiation of hepatocytes throughout the duration of exposure.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="149">These data are consistent with TCDD-induced oxidative DNA damage in female, but not male, Sprague Dawley rats (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-2">Wyde et al., 2000</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac48" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res41" novelty="None" advantage="None"/></s>
        <s sid="150">Additionally, in the current study, TCDD did not alter hepatocyte replication in male rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res42" novelty="None" advantage="None"/></s>
        <s sid="151">In female Sprague-Dawley rats, TCDD-induced cell proliferation (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-18">Wyde et al., 2001a</xref>), combined with oxidative DNA damage, may contribute to increased mutation frequency.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac49" novelty="None" advantage="None"/></s>
        <s sid="152">Subsequent mutations in altered or initiated hepatocytes may contribute to the progression of preneoplastic lesions to hepatocellular carcinomas in female rats.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp6" novelty="None" advantage="None"/></s>
        <s sid="153">This hypothesis is consistent with the sex-specific induction of liver tumors.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac50" novelty="None" advantage="None"/></s>
        <s sid="154">These data suggest that the induction of cell proliferation and oxidative DNA damage may be critical events in the mechanism of hepatocarcinogenesis by TCDD.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="155">The development of AHF has been demonstrated to reflect clonal expansion of a single initiated hepatocyte (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">Rabes et al., 1982</xref>; <xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-1">Scherer and Hoffmann, 1971</xref>; <xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-1">Tsuji et al., 1988</xref>; <xref class="xref-bibr" href="#ref-54" rid="xref-ref-54-1">Weinberg et al., 1987</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac51" novelty="None" advantage="None"/></s>
        <s sid="156">Therefore, the induction of the number of PGST-positive AHF/cm<sup>3</sup> by TCDD suggests additional conversion of normal hepatocytes to PGST-positive hepatocytes.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
        <s sid="157">These results are consistent with the induction of the number of PGST-positive AHF/cm<sup>3</sup> by TCDD in female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-19">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res43" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac52" novelty="None" advantage="None"/></s>
        <s sid="158">Additionally, E2 exposure alone induced the number of PGST-positive AHF/cm<sup>3</sup> but not the volume fraction in male rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res44" novelty="None" advantage="None"/></s>
        <s sid="159">These data suggest that more, but smaller, individual AHF may contribute to the same percentage of PGST-positive liver tissue.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="160">However, because neither TCDD nor E2 induce oxidative 8-oxo-dG DNA adducts in male Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-20">Wyde et al., 2001a</xref>), subsequent mutations to normal hepatocytes must be derived via an alternative mechanism.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac53" novelty="None" advantage="None"/></s>
        <s sid="161">No effect on PGST-positive volume fraction was observed after exposure to TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res45" novelty="None" advantage="None"/></s>
        <s sid="162">These data indicate that the growth of PGST-positive AHF was not induced by TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res46" novelty="None" advantage="None"/></s>
        <s sid="163">In contrast, TCDD induced the volume fraction of PGST-positive AHF in rats coexposed to TCDD and E2.<CoreSc1 atype="GSC" type="Res" conceptID="Res47" novelty="None" advantage="None"/></s>
        <s sid="164">Because the numbers of PGST-positive AHF/cm<sup>3</sup> were similar between E2-treated and cotreated rats, these data suggest that E2 potentiates TCDD-induced growth of PGST-positive AHF.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res48" novelty="None" advantage="None"/></s>
        <s sid="165">Although these data are consistent with TCDD induction of PGST-positive AHF in female rats regardless of hormonal status, they suggest a contribution of E2 to TCDD-induced promotion of the PGST-positive phenotype of AHF in male rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="166">Although the effects of TCDD and E2 on the development of PGST-positive AHF are not entirely consistent between male and female rats, previous studies suggest that PGST-positive AHF may not the most appropriate marker for assessing the effects of TCDD exposure on promotion.<CoreSc1 atype="GSC" type="Res" conceptID="Res49" novelty="None" advantage="None"/></s>
        <s sid="167">The GGT-positive AHF are more responsive to hormonal regulation of tumor promotion by TCDD and more appropriately reflect TCDD-induced molecular and pathological alterations in female rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-21">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac54" novelty="None" advantage="None"/></s>
        <s sid="168">The influence of ovarian hormones and E2 on TCDD-induced GGT-positive AHF is more consistent with TCDD-induced effects on cell proliferation (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-7">Lucier et al., 1991</xref>; <xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-22">Wyde et al., 2001a</xref>), oxidative DNA damage (<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-3">Tritscher et al., 1996</xref>; <xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-8">Wyde et al., 2001b</xref>), and sex-specific tumor induction (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-3">Kociba et al., 1978</xref>; <xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-3">NTP, 1982</xref>) than alterations in PGST-positive AHF.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac55" novelty="None" advantage="None"/></s>
        <s sid="169">Additionally, the relative potency of tumor promotion by TCDD in intact and OVX rats as determined by PGST-positive AHF are equivalent.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac56" novelty="None" advantage="None"/></s>
        <s sid="170">The promotional index for TCDD based on PGST-positive AHF is 4.56 &#215; 10<sup>6</sup> in intact rats and 3.25 &#215; 10<sup>6</sup> in OVX rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac57" novelty="None" advantage="None"/></s>
        <s sid="171">These data suggest that alterations of GGT-positive AHF may be more biologically relevant in assessing tumor promotional effects of TCDD (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-23">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
        <s sid="172">Therefore, inhibition of AHF development observed in the GGT-positive phenotype may be more accurate in evaluating the effect of E2 on tumor promotion by TCDD in male rats than the enhancement observed in the PGST-positive phenotype.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac58" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="173">Exposure to E2 significantly reduced hepatocyte replication and the development of GGT-positive AHF in male rats regardless of exposure to TCDD.<CoreSc1 atype="GSC" type="Res" conceptID="Res50" novelty="None" advantage="None"/></s>
        <s sid="174">These results are consistent with the hormonal responsiveness of GGT-positive AHF in female Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-24">Wyde et al., 2001a</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac59" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res51" novelty="None" advantage="None"/></s>
        <s sid="175">An increase in the development of GGT-positive AHF is reflected in the removal of ovarian hormones by ovariectomy.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac60" novelty="None" advantage="None"/></s>
        <s sid="176">Supplementation with E2 in OVX rats reduces GGT-positive AHF development regardless of TCDD exposure.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac61" novelty="None" advantage="None"/></s>
        <s sid="177">Although the absolute values for GGT-positive development are lower in E2-supplemented OVX rats than in intact or nonsupplemented rats, exposure to E2 in OVX female rats may contribute to the effect of TCDD on hepatic tumor promotion.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac62" novelty="None" advantage="None"/></s>
        <s sid="178">Lower absolute values for GGT-positive AHF parameters may reflect an inhibitory effect of supraphysiological levels of E2 (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-3">Wyde et al., 2000</xref>) on GGT-positive AHF.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac63" novelty="None" advantage="None"/></s>
        <s sid="179">Lower values were also observed in the current study in E2-treated male rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res52" novelty="None" advantage="None"/></s>
        <s sid="180">However, in male rats, GGT-positive AHF were not induced by TCDD in the presence of E2 exposure.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="181">This is reflected in differences in the promotion index of 2.7 &#215; 10<sup>6</sup> in rats receiving placebo pellets and 7.7 &#215; 10<sup>4</sup> in rats treated with E2 pellets.<CoreSc1 atype="GSC" type="Res" conceptID="Res53" novelty="None" advantage="None"/></s>
        <s sid="182">These data suggest that potentiation of TCDD-induced tumor promotion by E2 is specific to female rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="183">This study indicates that TCDD is capable of promoting the development of preneoplastic foci in male Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
        <s sid="184">However, continuous exposure to TCDD in male rats does not induce liver tumor incidence.<CoreSc1 atype="GSC" type="Res" conceptID="Res54" novelty="None" advantage="None"/></s>
        <s sid="185">Differences in response to TCDD in hepatocyte proliferation, oxidative DNA damage, and preneoplastic AHF development may account for sex differences in tumor response between male and female rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con14" novelty="None" advantage="None"/></s>
        <s sid="186">TCDD-induced cell proliferation and oxidative DNA damage in female Sprague-Dawley rats (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-25">Wyde et al., 2001a</xref>,<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-9">b</xref>) were not observed in male Sprague-Dawley rats after 30 weeks of exposure.<CoreSc1 atype="GSC" type="Res" conceptID="Res55" novelty="None" advantage="None"/></s>
        <s sid="187">Increased rates of mutation may result in highly proliferative hepatocytes that exhibit higher levels of DNA damage (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">Ames et al., 1993</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac64" novelty="None" advantage="None"/></s>
        <s sid="188">However, increased oxidative DNA damage and increased rates of cell proliferation are not observed in female Sprague-Dawley rats after 20 weeks of exposure (<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-26">Wyde et al., 2001a</xref>,<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-10">b</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac65" novelty="None" advantage="None"/></s>
        <s sid="189">These data suggest that the induction of cell proliferation and oxidative DNA damage may contribute to the progression of TCDD-induced preneoplastic lesions to tumors in female rats but not male rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con15" novelty="None" advantage="None"/></s>
        <s sid="190">Additionally, differences in the potency of promotion by TCDD in males and females may contribute to the sex specificity of tumor development.<CoreSc1 atype="GSC" type="Con" conceptID="Con16" novelty="None" advantage="None"/></s>
        <s sid="191">Although the number of preneoplastic AHF is suggested to plateau after extended periods of promotion, the growth of preneoplastic lesions is believed to continue until the development of hepatocellular carcinomas (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">Hendrich et al., 1986</xref>; <xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-3">Pitot et al., 1989</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac66" novelty="None" advantage="None"/></s>
        <s sid="192">Induction of AHF volume fraction in female rats is substantially greater than in male rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res56" novelty="None" advantage="None"/></s>
        <s sid="193">These data provide a mechanistic foundation for differences in hepatocarcinogenesis of TCDD between male and female Sprague-Dawley rats.<CoreSc1 atype="GSC" type="Con" conceptID="Con17" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-37">
        <s sid="194">The authors gratefully thank Louise Harris, Larry Judd, James Clark, John Seely, Bill Ross, Amy Kim, Diane Spencer, Page Myers, Jean Grassman, and Heather Vahdat for technical assistance and Nancy Ress and Dori Germolec for critical review of this work.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>REFERENCES</TITLE>
    </SEC>
  </BODY>
</PAPER>